RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill aims to boost power of standard myeloma treatment
Disease control Not yet recruitingThis early-stage trial is testing a new oral drug called selvigaltin (GB1211) when added to a standard three-drug combination for multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find the safest dose and understand the side effec…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New Two-Drug combo challenges standard care for returning blood cancer
Disease control Not yet recruitingThis study aims to see if a new two-drug combination (teclistamab and pomalidomide) works better than the current standard three-drug treatment for multiple myeloma that has come back after initial therapy. It will involve about 162 adults whose cancer has relapsed after one or t…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New Two-Drug combo tested against standard care for Tough-to-Treat blood cancer
Disease control Not yet recruitingThis study is for adults with high-risk multiple myeloma, a blood cancer, that has either returned after initial treatment or stopped responding to it. It compares a new two-drug combination (daratumumab + teclistamab) against two standard three-drug combinations. The main goal i…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Targeted radiation 'Warhead' tested in fight against Tough-to-Treat blood cancer
Disease control Not yet recruitingThis early-stage trial is testing a new, targeted radiation treatment for patients with high-risk multiple myeloma. The treatment involves an antibody that seeks out cancer cells and delivers a radioactive substance directly to them. This is given before a donor stem cell transpl…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC